Akèy › Limfom › Ohio › Cleveland
Etid klinik pou Limfom nan Cleveland, OH
14 etid pou Limfom ap chèche patisipan nan sit nan ak bò kote Cleveland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Ap rekriteFaz 1/2
- University Hospitals Seidman Cancer Center, Cleveland
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- University Hospitals Cleveland Medical Center, Cleveland
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Ap rekriteFaz 2
- Cleveland Clinic, Cleveland
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Ap rekriteFaz 2
- University Hospitals Cleveland Medical Center, Cleveland
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Ap rekriteFaz 2
- The Cleveland Clinic Foundation, Cleveland
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Ap rekriteFaz 3
- Research Site, Cleveland
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Cleveland Clinic, Cleveland
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Ap rekriteFaz 1/2
- Cleveland Clinic, Cleveland
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- Cleveland Clinical Taussig Cancer Center, Cleveland
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Ap rekriteFaz 1
- University Hospitals Cleveland Medical Center, Cleveland
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- Cleveland Clinic, Cleveland
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Cleveland Clinic, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Cleveland Clinic, Cleveland
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Ap rekriteFaz 1
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Etid Limfom nan lòt vil
- Houston, TX34 etid
- Boston, MA33 etid
- New York City, NY33 etid
- Washington, DC23 etid
- Baldwin Park, CA21 etid
- Chicago, IL20 etid
- Durham, NC17 etid
- St. Louis, MO15 etid
- Philadelphia, PA15 etid
- Edison, NJ12 etid
- Atlanta, GA12 etid
- Seattle, WA12 etid
Lòt etid nan Cleveland
- Kansè Poumon ki pa ti selil43 etid
- Kansè (tout kalite)36 etid
- Kansè nan tete35 etid
- Kansè pwostat34 etid
- Ensifizyans kadyak33 etid
- Kansè Metastatik30 etid
- Kansè ovè30 etid
- Kansè poumon26 etid
- Kansè kolorektal24 etid
- Maladi kadyovaskilè22 etid
- Kansè Endomèt20 etid
- Leksemi mieloïd egi20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.